Asset sale casts doubt over Astion Pharma’s future
The outlook for the Danish biotech company Astion Pharma has become muddled following the sale of rights to Canada's Cipher Pharma recently, says major shareholder Torben Rønje.
BY LONNI LYNGE
Late last month, the Danish biotech company Astion Pharma sold the global rights to three of its products to Canada’s Cipher Pharma for up to CAD 40 million, with CAD 6 million to be paid upfront. The three products Dermadexin, Pruridexin and ASF-1096 are all focused on inflammatory dermatological diseases.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian strikes historic Prostvac deal
For abonnenter
Danske: Genmab partner might accelerate launch
For abonnenter
One of Denmark’s biggest biotech deals fails to deliver
For abonnenter
